Wells Fargo & Company Aclaris Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 4,590 shares of ACRS stock, worth $17,442. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,590
Previous 4,590
-0.0%
Holding current value
$17,442
Previous $5,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ACRS
# of Institutions
84Shares Held
50.7MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$54.2 Million9.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$17.8 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$12.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.01MShares$11.4 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$10.5 Million0.11% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $253M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...